MDT better than expected EPS, higher guidance, upgraded
This certainly bodes well for the under perfoming medical product sector. Just maybe time to buy VOLC given massive under performance...could it finish the last month strong? It just needs some volume...a little momentum...we'll see. So far, the institutional sponsorship has been poor and a recent upgrade to $20 target was ignored (like every other analyst upgrade I have seen). Management could help with a buyback or significant news...but maybe the MDT news can help money flow into the sector. Asset managers can get some big catch-up returns by buying VOLC at $15 and taking it towards $20...an easy thing for them to do given the current lack of interest.